Corporate News: Latigo Biotherapeutics
Latigo Biotherapeutics (ticker: LTGO) closed its trading session on Thursday, 22 September 2026, with a 7.15 % increase, reaching USD 16.93 per share at 05:33 PM Central Europe. The company’s share supply stands at 66.2 million shares, yielding a market capitalization of USD 1 billion. Over the last 24 hours, USD 2.8 million of Latigo shares were traded, representing a trading volume of approximately 165 shares per minute.
Historical Performance
- 24‑hour change: +7.15 %
- 52‑week high: USD 25.93 (27 August 2026)
- 52‑week low: USD 13.50 (15 October 2026)
- 200‑day simple moving average: USD 19.46
- Month‑end decline (last month): –21.52 %
Company Overview
Latigo Biotherapeutics is a venture‑backed biotechnology company founded by Scott M. Wasserman. Mr. Wasserman previously served as Chief Medical Officer at Kailera Therapeutics and held senior development positions at Amgen. The company focuses on developing first‑in‑class, non‑opioid pain medicines.
Recent corporate activity includes Mr. Wasserman’s appointment to the board of Inhibikase Therapeutics, where his expertise in clinical development and regulatory strategy is expected to support Inhibikase’s phase‑3 program for pulmonary arterial hypertension. No additional public updates regarding Latigo’s product pipeline or financial performance were announced.
Related Stock Activity (24 Hours)
| Ticker | 24‑Hour Change | Current Price (USD) | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|
| ENOV | +0.58 % | 21.24 | 1.2 | – |
| GDRX | +1.42 % | 3.64 | 1.2 | 72.63 |
| ADIG | +3.63 % | 16.47 | 1.2 | 37.82 |
| OMER | –1.75 % | 16.60 | 1.2 | 11.33 |
| SVRA | –1.89 % | 4.60 | 1.2 | – |
Enovis (ENOV)
Enovis closed at USD 21.24, up 0.58 %. The company’s market capitalization is USD 1.2 billion. Analysts highlight a turnaround in the latest quarterly performance, with a modest positive earnings per share (EPS) projected for the current fiscal year. Revenue forecasts suggest a slight increase over the same quarter a year earlier, indicating continued improvement.
Goodrx (GDRX)
Goodrx closed at USD 3.64, up 1.42 %. Market capitalization remains at USD 1.2 billion. The current price‑to‑earnings ratio is 72.63.
Adi Global Distrib (ADIG)
Adi Global Distrib closed at USD 16.47, up 3.63 %. Market capitalization is USD 1.2 billion. The price‑to‑earnings ratio is 37.82.
Omeros (OMER)
Omeros closed at USD 16.60, down 1.75 %. Market capitalization is USD 1.2 billion. The price‑to‑earnings ratio is 11.33. The decline follows the European Medicines Agency’s rejection of Omeros’ investigational drug OMS721, increasing regulatory uncertainty and prompting a reassessment of the company’s prospects.
Savara (SVRA)
Savara closed at USD 4.60, down 1.89 %. Market capitalization is USD 1.2 billion. The company reported exploratory subgroup data from its Phase 2/3 IMPALA trial at the CHEST 2026 Annual Meeting, showing potential benefits of daily inhaled molgramostim in patients with autoimmune pulmonary alveolar proteinosis. The findings are consistent with earlier Phase 3 results, though the sample size remains limited.
Summary
Latigo Biotherapeutics experienced a notable intraday gain, driven by overall market momentum and the company’s strategic board appointment. While no new product or financial data were disclosed, the recent activity reflects continued investor interest in the company’s non‑opioid pain portfolio and its leadership’s clinical expertise. Related biotech stocks displayed a mix of modest gains and declines, underscoring the sector’s sensitivity to regulatory decisions and clinical outcomes.
